{'fraction_non_alphanumeric': 0.033073929961089495, 'fraction_numerical': 0.0, 'mean_word_length': 5.602564102564102, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Therapeutic Potential of AICAR in Attenuating Obesity‐Induced Metabolic, Liver and Kidney Disease

Obesity is a risk factor for organ inflammation, diabetes, and kidney disease. Here we evaluated the therapeutic potential of AICAR (an AMPK activator) in obesity‐induced metabolic, kidney and liver disease with High‐Fat‐Diet (HFD) in wild type and adiponectin‐deficient mice. We also correlate our findings to human pathophysiology, by examining human tissue responses to AICAR ex vivo in a proof of concept study.